World's Best Scientists 2026 revealed!
Robert S. Kerbel

Robert S. Kerbel

Award Badge
Medicine
Canada
2023

D-Index & Metrics

Medicine

D-Index
126
Citations
65748
World Ranking
2933
National Ranking
121

Research.com Recognitions

  • 2023 - Research.com Medicine in Canada Leader Award

Overview

Robert S. Kerbel is affiliated with the University of Toronto in Canada. Their research activities span multiple fields, primarily in Medicine and Biochemistry, Genetics and Molecular Biology, with notable contributions to Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research, and Immunology.

The main topics covered in their work include:

  • Angiogenesis and VEGF in Cancer
  • Cancer Immunotherapy and Biomarkers
  • Cell Adhesion Molecules Research
  • Immunotherapy and Immune Responses
  • Prostate Cancer Treatment and Research
  • Cancer Genomics and Diagnostics
  • Renal cell carcinoma treatment

Frequent co-authors in their publications include:

  • Kabir A. Khan (8 publications)
  • William Cruz-Muñoz (4 publications)
  • Shan Man (3 publications)
  • Hanzhi Wang (3 publications)
  • Xiaoyong Huang (3 publications)

The scientist has published several papers in recurring venues, with multiple works appearing in:

  • Cancer Research (5 publications)
  • EMBO Molecular Medicine (3 publications)
  • Nature Reviews Clinical Oncology
  • Science Immunology
  • npj Breast Cancer

Notable recent publications include:

  • "Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials," 2024, Nature Reviews Clinical Oncology
  • "Tumors resurrect an embryonic vascular program to escape immunity," 2022, Science Immunology
  • "Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer," 2021, EMBO Molecular Medicine
  • "Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer," 2020, npj Breast Cancer
  • "Metronomic chemotherapy offsets HIFα induction upon maximum-tolerated dose in metastatic cancers," 2020, EMBO Molecular Medicine

Best Publications

  • Angiogenesis as a therapeutic target

    Napoleone Ferrara;Robert S. Kerbel

  • Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

    John M.L. Ebos;Christina R. Lee;William Cruz-Munoz;Georg A. Bjarnason

  • Clinical translation of angiogenesis inhibitors.

    Robert Kerbel;Judah Folkman

  • The anti-angiogenic basis of metronomic chemotherapy

    Robert S. Kerbel;Barton A. Kamen

  • Tumor angiogenesis: past, present and the near future.

    Robert S. Kerbel

  • Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

    Giannoula Klement;Sylvain Baruchel;Janusz Rak;Shan Man

  • Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

    Alicia M. Viloria Petit;Janusz Rak;Mien Chie Hung;Patricia Rockwell

  • Establishment and Characterization of First Trimester Human Trophoblast Cells with Extended Lifespan

    Charles H. Graham;Teresa S. Hawley;Robert C. Hawley;John R. MacDougall

  • Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.

    J. Rak;Y. Mitsuhashi;L. Bayko;J. Filmus

  • Antiangiogenic therapy in oncology: current status and future directions.

    Gordon C Jayson;Robert Kerbel;Lee M Ellis;Adrian L Harris

  • Antiangiogenic therapy: impact on invasion, disease progression, and metastasis

    John M. L. Ebos;Robert S. Kerbel

  • Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR

    Khalid Al-Nedawi;Brian Meehan;Robert S. Kerbel;Anthony C. Allison

  • The multifaceted circulating endothelial cell in cancer: towards marker and target identification

    Francesco Bertolini;Yuval Shaked;Patrizia Mancuso;Robert S. Kerbel

  • Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors

    Yuval Shaked;Alessia Ciarrocchi;Marcela Franco;Christina R. Lee

  • Acquired Resistance to the Antitumor Effect of Epidermal Growth Factor Receptor-blocking Antibodies in Vivo A Role for Altered Tumor Angiogenesis

    Alicia Viloria-Petit;Tania Crombet;Serge Jothy;Daniel Hicklin

  • E-Cadherin–dependent Growth Suppression is Mediated by the Cyclin-dependent Kinase Inhibitor p27KIP1

    Brad St. Croix;Capucine Sheehan;Janusz W. Rak;Vivi Ann Flørenes

  • A role for survivin in chemoresistance of endothelial cells mediated by VEGF.

    Jennifer Tran;Zubin Master;Joanne L. Yu;Janusz Rak

  • Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents.

    Robert S. Kerbel

  • Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.

    Francesco Bertolini;Saki Paul;Patrizia Mancuso;Silvia Monestiroli

  • Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?

    Robert S. Kerbel

Frequent Co-Authors

Francesco Bertolini
Francesco Bertolini European Institute of Oncology
Daniel J. Hicklin
Daniel J. Hicklin Eli Lilly (United States)
F. Stuart Foster
F. Stuart Foster University of Toronto
Jorge Filmus
Jorge Filmus Sunnybrook Health Science Centre
Daniel J. Dumont
Daniel J. Dumont University of Toronto
James W. Dennis
James W. Dennis Lunenfeld-Tanenbaum Research Institute
Martin L. Breitman
Martin L. Breitman University of Toronto
Kathleen I. Pritchard
Kathleen I. Pritchard University of Toronto
Peter B. Vermeulen
Peter B. Vermeulen University of Antwerp
Romano Danesi
Romano Danesi University of Pisa

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in studying Medicine in the USA, there are many alternative online degrees and career pathways to consider—especially in nursing, which remains in high demand nationwide. For those already holding a nursing license, advancing your career can be made more affordable through the online nursing doctorate programs. These programs allow working professionals to pursue advanced practice and leadership roles while maintaining flexibility.

For registered nurses looking to complete their bachelor's degree, the cheapest online bsn programs are a cost-effective way to boost credentials and expand career opportunities. If you're coming from a non-nursing background but want to enter the field quickly, consider the online direct entry msn programs for non-nursing majors. These accelerated options help students transition into nursing without prior experience.

Finally, applicants concerned about competitiveness may find more accessible entry points through nursing schools with high acceptance rates. Exploring these options can help you fast-track your journey into healthcare, regardless of your starting point.

Best Scientists Citing Robert S. Kerbel

Trending Scientists